IL148304A0 - Oligonucleotide n3'-p5' thiophosphoramidates, their synthesis and use - Google Patents

Oligonucleotide n3'-p5' thiophosphoramidates, their synthesis and use

Info

Publication number
IL148304A0
IL148304A0 IL14830400A IL14830400A IL148304A0 IL 148304 A0 IL148304 A0 IL 148304A0 IL 14830400 A IL14830400 A IL 14830400A IL 14830400 A IL14830400 A IL 14830400A IL 148304 A0 IL148304 A0 IL 148304A0
Authority
IL
Israel
Prior art keywords
oligonucleotides
oligonucleotide
thiophosphoramidates
synthesis
inventive
Prior art date
Application number
IL14830400A
Other languages
English (en)
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of IL148304A0 publication Critical patent/IL148304A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6832—Enhancement of hybridisation reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
IL14830400A 1999-09-10 2000-09-08 Oligonucleotide n3'-p5' thiophosphoramidates, their synthesis and use IL148304A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15320199P 1999-09-10 1999-09-10
US16044499P 1999-10-19 1999-10-19
PCT/US2000/024688 WO2001018015A1 (en) 1999-09-10 2000-09-08 Oligonucleotide n3'→p5' thiophosphoramidates: their synthesis and use

Publications (1)

Publication Number Publication Date
IL148304A0 true IL148304A0 (en) 2002-09-12

Family

ID=26850281

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14830400A IL148304A0 (en) 1999-09-10 2000-09-08 Oligonucleotide n3'-p5' thiophosphoramidates, their synthesis and use
IL148304A IL148304A (en) 1999-09-10 2002-02-21 Oligonucleotide N3'-P5 'thioposphoramidates, synthesis and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL148304A IL148304A (en) 1999-09-10 2002-02-21 Oligonucleotide N3'-P5 'thioposphoramidates, synthesis and their uses

Country Status (17)

Country Link
US (5) US6608036B1 (zh)
EP (2) EP1992634A1 (zh)
JP (2) JP4267233B2 (zh)
KR (2) KR20070112295A (zh)
CN (1) CN1317291C (zh)
AT (1) ATE391134T1 (zh)
AU (2) AU767646B2 (zh)
CA (1) CA2382521C (zh)
CY (1) CY1108158T1 (zh)
DE (1) DE60038495T2 (zh)
DK (1) DK1210357T3 (zh)
ES (1) ES2302701T3 (zh)
HK (1) HK1049339B (zh)
IL (2) IL148304A0 (zh)
MX (1) MXPA02002577A (zh)
PT (1) PT1210357E (zh)
WO (1) WO2001018015A1 (zh)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523389A (en) * 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US20030032610A1 (en) * 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
RU2233844C2 (ru) 1999-02-12 2004-08-10 Санкио Компани Лимитед Новые нуклеозидные и олигонуклеотидные аналоги
WO2001018015A1 (en) * 1999-09-10 2001-03-15 Geron Corporation Oligonucleotide n3'→p5' thiophosphoramidates: their synthesis and use
AU2001251115A1 (en) 2000-03-31 2001-10-15 Trustees Of Boston University Use of locally applied dna fragments
AU2003244338C1 (en) * 2001-03-23 2008-07-24 Geron Corporation Oligonucleotide conjugates
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
CA2440322C (en) * 2001-03-23 2014-09-09 Geron Corporation Oligonucleotide conjugates
DE10159904A1 (de) * 2001-12-06 2003-07-03 Adnagen Ag Oligonukleotidanordnung, Verfahren zum Nukleotidnachweis sowie Vorrichtung hierfür
WO2004037842A1 (ja) * 2002-10-23 2004-05-06 Sankyo Company, Limited 糖部ｓ型配座の新規人工核酸
CA2528483C (en) 2003-06-23 2012-04-10 Geron Corporation Compositions and methods for increasing telomerase activity
US9248088B2 (en) 2003-06-25 2016-02-02 Telomerase Activation Sciences, Inc. Compositions and methods for skin conditioning
NZ545516A (en) * 2003-09-09 2009-06-26 Geron Corp Modified oligonucleotides for telomerase inhibition
DE602004031975D1 (de) 2003-11-04 2011-05-05 Geron Corp Rna-amidate und thioamidateur rnai
EP1783216A1 (en) * 2004-05-28 2007-05-09 Sankyo Company, Limited Telomerase-inhibitory ena oligonucleotide
LT3296312T (lt) 2004-07-02 2021-06-10 Geron Corporation Apsaugotų 3'-amino-5'-fosforamidito nukleozido monomerų sintezė
EP1828217A2 (en) * 2004-12-16 2007-09-05 Febit Biotech GmbH Polymerase-independent analysis of the sequence of polynucleotides
WO2006113426A2 (en) * 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
US8153604B2 (en) 2006-04-24 2012-04-10 Geron Corporation CNS-tumor treatment method and composition
TR201819789T4 (tr) * 2006-10-30 2019-01-21 Geron Corp Kanser tedavisine yönelik gemsitabin ve kombine telomeraz inhibitörü.
WO2008094640A2 (en) 2007-01-30 2008-08-07 Geron Corporation Compounds having anti-adhesive effects on cancer cells
US8011527B2 (en) * 2007-08-10 2011-09-06 Rexam Beverage Can Company Can end with countersink
PT3330383T (pt) 2008-10-17 2020-05-06 Geron Corp Grn163l para utiliização como inibidor de telomerase no tratamento de cancro
CN102348712A (zh) 2009-01-09 2012-02-08 卡迪夫大学学院顾问有限公司 用于治疗病毒感染的鸟苷核苷类化合物的磷酰胺酯衍生物
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9593137B2 (en) 2011-12-22 2017-03-14 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
WO2013148186A1 (en) 2012-03-26 2013-10-03 President And Fellows Of Harvard College Lipid-coated nucleic acid nanostructures of defined shape
CA2887702C (en) * 2012-10-26 2023-08-01 Geron Corporation C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
US9228189B2 (en) 2012-10-26 2016-01-05 Geron Corporation C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3578652B1 (en) 2013-03-15 2023-07-12 ModernaTX, Inc. Ribonucleic acid purification
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
EP3578663A1 (en) 2013-03-15 2019-12-11 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
WO2014152030A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Removal of dna fragments in mrna production process
CN103382212B (zh) * 2013-07-06 2016-08-31 中国科学院成都生物研究所 5′位改性嘌呤霉素化合物及其制备方法和用途
PT3019619T (pt) 2013-07-11 2021-11-11 Modernatx Inc Composições que compreendem polinucleótidos sintéticos que codificam proteínas relacionadas com crispr e sgarn sintéticos e métodos de utilização
EP3052512A4 (en) 2013-09-30 2017-02-22 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
JP2017505104A (ja) * 2013-11-08 2017-02-16 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド インビボにおける薬剤送達のための核酸ナノ構造体
WO2015095527A1 (en) 2013-12-20 2015-06-25 The General Hosptial Corporation Methods and assays relating to circulating tumor cells
JOP20200257A1 (ar) * 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US20170204152A1 (en) * 2014-07-16 2017-07-20 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3169335B8 (en) 2014-07-16 2019-10-09 ModernaTX, Inc. Circular polynucleotides
ME03811B (me) 2015-04-23 2021-04-20 Geron Corp Postupci za pripremu polinukleotida upotrebom kompozicija multivalentne katjonske soli
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
WO2018053185A1 (en) * 2016-09-14 2018-03-22 Alios Biopharma, Inc. Modified oligonucleotides and methods of use
JP2019534862A (ja) * 2016-09-20 2019-12-05 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト ホスホルアミダイト化学を使用する骨格修飾モルホリノオリゴヌクレオチド及びキメラの合成
US20180179542A1 (en) * 2016-11-11 2018-06-28 Alios Biopharma, Inc. OLIGONUCLEOTIDE TARGETING STRATEGY FOR cccDNA
WO2018221735A1 (ja) * 2017-06-02 2018-12-06 富田製薬株式会社 新規オリゴヌクレオチド
HRP20211940T1 (hr) * 2017-07-10 2022-03-18 Geron Corporation Poboljšani postupak za pripremanje imetelstata
WO2019053659A1 (en) * 2017-09-14 2019-03-21 Alios Biopharma, Inc. PHOSPHORAMIDITES OF MODIFIED NUCLEOSIDES
EA202092156A1 (ru) * 2018-03-13 2021-04-01 Янссен Фармацевтика Нв Модифицированные олигонуклеотиды и способы применения в лечении таупатий
EP3802821A4 (en) * 2018-05-25 2022-06-08 New York Institute of Technology DIRECT NUCLEIC ACID SEQUENCING METHOD
WO2020009702A1 (en) 2018-07-05 2020-01-09 Agilent Technologies, Inc. Double coupling method for oligonucleotide synthesis
US20230250125A1 (en) 2020-04-01 2023-08-10 Janssen Biopharma, Inc. Nucleic acid polymers

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4647529A (en) 1984-06-01 1987-03-03 Rodland Karin D Hybridization method of detecting nucleic acid sequences with probe containing thionucleotide
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5109124A (en) 1988-06-01 1992-04-28 Biogen, Inc. Nucleic acid probe linked to a label having a terminal cysteine
US5501959A (en) 1989-01-17 1996-03-26 Alamar Biosciences Laboratory, Inc. Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5506212A (en) 1990-01-11 1996-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides with substantially chirally pure phosphorothioate linkages
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US6017895A (en) 1992-02-10 2000-01-25 Genzyme Corporation Oligonucleotides possessing zwitterionic moieties
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5645986A (en) * 1992-05-13 1997-07-08 Board Of Reagents, The University Of Texas System Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US5654286A (en) * 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
JPH09500378A (ja) 1993-07-02 1997-01-14 リンクス セラピューティクス，インコーポレイティド 枝分れされそして複雑に結合された高分子構造体の集中的合成
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
HUT76094A (en) * 1994-03-18 1997-06-30 Lynx Therapeutics Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
CN1231491C (zh) 1994-07-07 2005-12-14 杰龙公司 哺乳动物端粒酶
US5972605A (en) 1994-07-07 1999-10-26 Geron Corporation Assays for regulators of mammalian telomerase expression
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5776679A (en) 1994-07-07 1998-07-07 Geron Corporation Assays for the DNA component of human telomerase
US5643890A (en) * 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US6004939A (en) 1995-07-06 1999-12-21 Ctrc Research Foundation Board Of Regents Methods for modulation and inhibition of telomerase
US5968506A (en) * 1995-08-04 1999-10-19 Geron Corporation Purified telomerase
US5856096A (en) * 1995-09-20 1999-01-05 Ctrc Research Foundation Rapid and sensitive assays for detecting and distinguishing between processive and non-processive telomerase activities
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
AU6321696A (en) 1996-04-05 1997-10-29 German Viktorovich Demidov Transportation power unit with energetic module
US6015710A (en) * 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
WO1997037691A1 (en) 1996-04-10 1997-10-16 Lynx Therapeutics, Inc. Telomerase inhibitors
EP0912761A4 (en) * 1996-05-29 2004-06-09 Cornell Res Foundation Inc DETERMINATION OF DIFFERENCES IN THE NUCLEIC ACID SEQUENCE BY MEANS OF A COMBINATION OF LIGASE DETERMINATION AND POLYMERASE CHAIN REACTION
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
WO1998014592A2 (en) 1996-10-01 1998-04-09 Geron Corporation Telomerase reverse transcriptase
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
DE19720151A1 (de) * 1997-05-02 1998-11-05 Max Delbrueck Centrum Chimäre Oligonucleotide und ihre Verwendung
JPH11228451A (ja) * 1998-02-10 1999-08-24 Kureha Chem Ind Co Ltd 抗癌性増強医薬組成物
WO2001018015A1 (en) * 1999-09-10 2001-03-15 Geron Corporation Oligonucleotide n3'→p5' thiophosphoramidates: their synthesis and use
AU2001249723A1 (en) 2000-03-31 2001-10-15 Geron Corporation Telomerase inhibitor polynucleotides
US6342358B1 (en) 2000-08-24 2002-01-29 The Regents Of The University Of California Human telomerase RNA elements
US7354706B2 (en) * 2003-09-09 2008-04-08 The Regents Of The University Of Colorado, A Body Corporate Use of photopolymerization for amplification and detection of a molecular recognition event

Also Published As

Publication number Publication date
DE60038495D1 (de) 2008-05-15
KR20070112295A (ko) 2007-11-22
AU2003262453A1 (en) 2003-12-18
KR100858465B1 (ko) 2008-09-16
EP1210357A1 (en) 2002-06-05
HK1049339B (zh) 2008-06-27
WO2001018015A1 (en) 2001-03-15
EP1992634A1 (en) 2008-11-19
US20140349292A1 (en) 2014-11-27
CA2382521C (en) 2009-08-25
MXPA02002577A (es) 2003-10-14
KR20020092909A (ko) 2002-12-12
DK1210357T3 (da) 2008-07-21
PT1210357E (pt) 2008-06-11
US20070037770A1 (en) 2007-02-15
JP2009046483A (ja) 2009-03-05
JP4267233B2 (ja) 2009-05-27
JP2003513887A (ja) 2003-04-15
CN1317291C (zh) 2007-05-23
AU7360900A (en) 2001-04-10
AU767646B2 (en) 2003-11-20
CY1108158T1 (el) 2014-02-12
US7138383B2 (en) 2006-11-21
DE60038495T2 (de) 2009-04-09
IL148304A (en) 2007-10-31
US6835826B2 (en) 2004-12-28
CA2382521A1 (en) 2001-03-15
US6608036B1 (en) 2003-08-19
US20030212032A1 (en) 2003-11-13
ES2302701T3 (es) 2008-08-01
HK1049339A1 (en) 2003-05-09
ATE391134T1 (de) 2008-04-15
US20050049408A1 (en) 2005-03-03
EP1210357B1 (en) 2008-04-02
CN1373768A (zh) 2002-10-09

Similar Documents

Publication Publication Date Title
IL148304A0 (en) Oligonucleotide n3'-p5' thiophosphoramidates, their synthesis and use
NO963891D0 (no) Oligonukleotid N3'-> P5' fosforamidater: Syntese og forbindelser; hybridiserings- og nukleaseresistanse-egenskaper
KR0133131B1 (en) Peptide nucleic acids
PT937098E (pt) Clonagem recombinatoria in vitro utilizando locais de recombinacao modificados
CA2223678A1 (en) Covalently linked oligonucleotide minor groove binder conjugates
CY1105109T1 (el) Διαδικασια για την παρασκευη μικρου μοριακου βαρους πολυαιθυλενιμινης
CA2006008A1 (en) Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
DK0804456T3 (da) Peptid-nukleinsyre-konjugater
MXPA01010488A (es) Secuencias de acidos nucleicos para proteinas que intervienen en sintesis isoprenoide.
DE69636288D1 (de) Samenstrenung resistenz
AU4879096A (en) Multiple-tumor aberrant growth genes
CY1106041T1 (el) Καινοφανης συλλεκτινη
CA2382631A1 (en) Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
NZ297023A (en) method of the purification of double-stranded DNA using an oligonucleotide coupled covanlenty to a support
WO1996015240A3 (en) Ribozyme analogs
ATE366818T1 (de) Hirse-spezifische verzwergungsgene und verfahren ihrer anwendung
EP0777730A4 (en) DNA VECTOR FOR BONE-SPECIFIC GENE EXPRESSION
Lee et al. Mitochondrial DNA Restriction Fragment Length Polymorphism in Korean

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed